Compare IPAR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | TVTX |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1995 | 2013 |
| Metric | IPAR | TVTX |
|---|---|---|
| Price | $91.73 | $40.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $116.60 | $40.46 |
| AVG Volume (30 Days) | 223.0K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | 2.34 | ★ 92.89 |
| EPS | ★ 5.24 | N/A |
| Revenue | ★ $1,317,700,000.00 | N/A |
| Revenue This Year | $3.86 | $44.76 |
| Revenue Next Year | $7.89 | $35.51 |
| P/E Ratio | $17.37 | ★ N/A |
| Revenue Growth | ★ 21.26 | N/A |
| 52 Week Low | $77.21 | $13.88 |
| 52 Week High | $142.50 | $43.31 |
| Indicator | IPAR | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 65.65 |
| Support Level | $87.60 | $32.62 |
| Resistance Level | $99.02 | $42.06 |
| Average True Range (ATR) | 2.84 | 2.14 |
| MACD | -0.11 | 0.56 |
| Stochastic Oscillator | 27.67 | 80.49 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.